Profile data is unavailable for this security.
About the company
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
- Revenue in USD (TTM)93.76m
- Net income in USD-13.68m
- Incorporated2015
- Employees150.00
- LocationAytu Biopharma Inc7900 E. Union Avenue, Suite 920DENVER 80237United StatesUSA
- Phone+1 (720) 437-6580
- Fax+1 (302) 636-5454
- Websitehttps://aytubio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | 0.00 | -30.83m | 16.94m | 13.00 | -- | 0.6015 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.17m | 17.23m | 3.00 | -- | 3.72 | -- | -- | -0.0184 | -0.0184 | 0.00 | 0.0269 | 0.00 | -- | -- | 0.00 | -34.05 | 27.48 | -34.48 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -26.77m | 17.29m | 1.00 | -- | 3.61 | -- | 2,882.25 | -1.67 | -1.67 | 0.0004 | 0.2996 | 0.0002 | -- | 12.00 | 6,000.00 | -97.94 | -74.83 | -147.22 | -89.57 | -- | -- | -446,233.30 | -10,508.06 | -- | -19.25 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 17.39m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -37.28m | 17.61m | 35.00 | -- | 0.609 | -- | 1,761.17 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 17.62m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Talphera Inc | 651.00k | -14.31m | 17.67m | 15.00 | -- | 1.08 | -- | 27.15 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 17.71m | 150.00 | -- | 0.5753 | -- | 0.1889 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| Biora Therapeutics Inc | 544.00k | -111.08m | 17.83m | 58.00 | -- | -- | -- | 32.78 | -7.13 | -7.12 | 0.0267 | -3.29 | 0.0143 | -- | 0.6594 | 9,379.31 | -291.43 | -122.84 | -482,965.20 | -369.01 | -- | -- | -20,419.48 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 18.07m | 131.00 | -- | -- | -- | 1.92 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 18.09m | 2.00 | -- | 0.5812 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -39.55m | 18.31m | 43.00 | -- | 2.75 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Synlogic Inc | 3.21m | -73.22m | 18.50m | 6.00 | -- | 1.38 | -- | 5.77 | -10.62 | -10.62 | 0.4576 | 1.15 | 0.0495 | -- | -- | 534,166.70 | -113.09 | -40.57 | -134.57 | -43.82 | -- | -- | -2,284.68 | -3,245.93 | -- | -- | 0.00008 | -- | 185.68 | 5.99 | 13.40 | -- | -48.05 | -- |
Data as of May 24 2024. Currency figures normalised to Aytu Biopharma Inc's reporting currency: US Dollar USD
31.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.09m | 19.52% |
| Stonepine Capital Management LLCas of 31 Mar 2024 | 472.47k | 8.49% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 71.32k | 1.28% |
| Geode Capital Management LLCas of 31 Mar 2024 | 34.56k | 0.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 27.89k | 0.50% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 22.79k | 0.41% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 15.24k | 0.27% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 14.62k | 0.26% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 14.56k | 0.26% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 13.88k | 0.25% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
